Tigecycline is the first in a new class of antibacterial agents, the glycylcyclines. Although derived from tetracycline agents, tigecycline is structurally modified to overcome common tetracycline-resistance mechanisms, including ribosomal protection and efflux pumps. It possesses a broad spectrum of antibacterial activity ,including activity against some MDR Gram-positive and -negative pathogens. The safety and efficacy of tigecycline has been demonstrated in clinical trials and it is currently indicated for the management of cSSIs and cIAIs in adult patients. Further experience with tigecycline for serious infections with drug-resistant pathogens is currently warranted.
Expert Rev Anti Infect Ther. 2008;6(5):557-567. © 2008 Expert Reviews Ltd.
No writing assistance was utilized in the production of this manuscript.
Cite this: Establishing the Role of Tigecycline in an era of Antimicrobial Resistance - Medscape - Oct 01, 2008.